Predicting the future is famously a mug’s game. Between Covid-19, drug pricing legislation, and a dramatic turn of events in neuroscience, the last few years of biotech history have been volatile to the point of capriciousness.
So instead of guessing at what the year ahead may bring, here instead are a few of the trends that will likely be staging grounds for the next major plot twists, including an escalating scramble for all-important cash and an invocation of a time-honored pharmaceutical cliché.
Getting creative to raise money
Despite the breathless promises of countless AI startups, the process of inventing drugs is probably not going to get significantly faster or cheaper any time soon. That means the cash-burning companies doing the expensive work of making medicines are going to need to raise money, which, in 2023, will likely require a little creativity.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect